Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer
- 554 Downloads
The fourth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer was published in 2015. The guidelines contain seven chapters and six flow charts. The major changes in this new edition are as follows—(1) the format has been changed from reviews to clinical questions (CQ), and the guidelines for optimal clinical practice in Japan are now shown as 41 CQs and answers; (2) the ‘flow charts’ have been improved and placed near the beginning of the guidelines; (3) the ‘basic points’, including tumor staging, histological classification, surgical procedures, chemotherapy, and palliative care, are described before the chapter; (4) the FIGO surgical staging of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was revised in 2014 and the guideline has been revised accordingly to take the updated version of this classification into account; (5) the procedures for examination and management of hereditary breast and ovarian cancer are described; (6) information on molecular targeting therapy has been added; (7) guidelines for the treatment of recurrent cancer based on tumor markers alone are described, as well as guidelines for providing hormone replacement therapy after treatment.
KeywordsGuideline Ovarian cancer Primary peritoneal cancer Fallopian tube cancer Japan Society of Gynecologic Oncology
Creation of this guideline was supported by the Japan Society of Gynecologic Oncology with contributions from “Encouragement of wider use of practice guidelines for cancer and their effects, as well as investigation of guideline projects” (chief investigator: Koichi Hirata), Research for Promotion of Cancer Control Programmes (2014), and a Health and Labour Sciences Research Grant. The funding sources did not influence the contents of this guideline.
Conflict of interest
The conflict-of-interest committee of the Japan Society of Gynecologic Oncology checked conflicts of interest for the people involved in creating and evaluating this guideline and their associates (i.e., marital partner, first-degree relatives, or people sharing income/assets), according to the “Guidelines for conflict of interest issues in clinical studies on cancer” (http://www.jsgo.or.jp/topics/index01.html) published by the Japan Society of Gynecologic Oncology. Although there were conflicts of interest for some contributors through research/lecture activities supported by companies, the recommendations in this guideline are based on scientific evidence and have not been influenced by the interests of a specific organization and are not biased in recommending or products or techniques.
- 1.Cancer Mortality in Japan (2012) Center for Cancer Control and Information Services. National Cancer Center, Japan. http://ganjoho.jp/professional/statistics/statistics.html. Accessed 15 Sept 2014
- 3.Gynecologic Cancer Committee (2012) Gynecologic cancer committee report in 2011. Acta Obstet Gynaecol Jpn 66:1024–1038Google Scholar
- 6.Fukui T, Yoshida M, Yamaguchi N (2007) Minds Guidance of practice guidelines 2007. Igakushoin, TokyoGoogle Scholar
- 8.Japanese Society of Clinical Oncology clinical practice guidelines 2013 for G-CSF. http://www.jsco-cpg.jp/item/30/index.html